Sanofi

The European Commission’s decision will make the product the first disease-modifying treatment to be available for the condition in Europe. The European Commission has approved Teizeild (teplizumab) as the first …

Sanofi announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its supplemental Biologics License Application (sBLA) for Tzield (teplizumab-mzwv) targeting young children with stage 2 …

Sanofi could be months away from wider US approval for Tzield, its first-in-class drug for delaying the progression of type 1 diabetes (T1D), in children as young as one. The …

Toronto, February 20, 2024 /CNW/ – JDRF and Sanofi Canada have announced a partnership aimed at raising awareness of the chronic autoimmune disease type 1 diabetes (T1D) and the role …